The Relationship of Gonadotropin-releasing Hormone Agonists and Anthropometric Indices of Girls with Premature Idiopathic Central Precocious Puberty: A Cohort Study

Document Type : Original Article

Authors

1 1.Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran 2. Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Pediatric Diseases, Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

6 Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran

7 Department of Pediatric Endocrinology and Metabolism, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: This study aims to determine the effect of different GnRH agonist brands on body mass index (BMI), weight, and height in patients referred to the pediatric endocrinology clinic of Akbar Hospital.
Methods: In this cohort study, 80 girls aged 5-8 years diagnosed with precocious puberty cases were included according to the Tanner staging and at the second puberty stage. The patients were classified into three groups of GnRH agonists, A, B, and C, receiving Diphereline, Microrelin, and Variopeptyl, respectively. Height, weight, and BMI were calculated every three months.
Results: In group A, the weight (P=0.007) and BMI (P<0.001) percentiles and weight (P=0.024) and height (P=0.021) Z-scores were significantly increased compared to the baseline. In group B, the weight (P=0.024) and height (P=0.020) Z-scores also increased at the end of the study. However, the changes in group C were not significant. In addition, the weight, height, and BMI Z-scores were significantly increased in normal-weight subjects compared to overweight and obese participants. The results of comparing the changes in the weight and height between the three-drug groups showed no significant difference (P=0.142 and 0.161, respectively).
Conclusion: The findings of this study revealed that GnRH agonists could increase height, weight, and BMI; however, this increase was not significant for one type of GnRH agonist. Future prospective long-term follow-up studies are required to elucidate whether GnRH treatment affects final adult weight and height and clarify the difference between various types of GnRH agonists among participants with diverse health statuses.
 

Keywords

References

  1. Rhie YJ, Lee KH, Ko JM, Lee WJ, Kim JH, Kim HS. KISS1 gene polymorphisms in Korean girls with central precocious puberty. J Korean Med Sci. 2014;29(8):1120-1125.
  2. Simsek E, Demiral M, Ceylaner S, Kırel B. Two frameshift mutations in MKRN3 in Turkish patients with familial central precocious puberty. Horm Res Paediatr. 2017;87(6):405-411.
  3. Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Management of endocrine disease: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016;174(3):R79-87.
  4. Kim SH, Huh K, Won S, Lee KW, Park MJ. A Significant Increase in the Incidence of Central Precocious Puberty among Korean Girls from 2004 to 2010. PLoS One. 2015;10(11):e0141844.
  5. Soriano-Guillén L, Corripio R, Labarta JI, Cañete R, Castro-Feijóo L, Espino R, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95(9):4305-4013.
  6. Kumar M, Mukhopadhyay S, Dutta D. Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective. Indian J Endocrinol Metab. 2015;19(2):228-235.
  7. Bahardoust M, Mousavi S, Ziafati H, Alipour H, Haghmoradi M, Olamaeian F, Tayebi A, Tizmaghz A. Vitamin B12 deficiency after total gastrectomy for gastric cancer, prevalence, and symptoms: a systematic review and meta-analysis. Eur J Cancer Prev. 2024;33(3):208-216.
  8. Carel J-C, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Group motE-LGACC. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-762.
  9. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update. 2004;10(2):135-147.
  10. Breyer P, Haider A, Pescovitz OH. Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clin Obstet Gynecol. 1993;36(3):764-772.
  11. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf). 2002;56(2):129-148.
  12. De Kroon ML, Renders CM, Van Wouwe JP, Van Buuren S, Hirasing RA. The Terneuzen Birth Cohort: BMI change between 2 and 6 years is most predictive of adult cardiometabolic risk. PloS one. 2010;5(11):e13966.
  13. Barker DJ, Osmond C, Forsén TJ, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005;353(17):1802-1809.
  14. Danaie M, Yeganegi M, Dastgheib SA, Bahrami R, Jayervand F, Rahmani A, et al. The interaction of breastfeeding and genetic factors on childhood obesity. Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 9;23:100334.
  15. Shiasi Arani K, Heidari F. Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls. Int J Endocrinol Metab. 2015;13(3):e23085.
  16. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010;95(1):109-117.
  17. Głab E, Barg E, Wikiera B, Grabowski M, Noczyńska A. Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab. 2009;15(1):7-11.
  18. Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, Lorini R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol. 2005;153(3):463-464.
  19. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab. 1999; 84(12):4480-4488.
  20. Anık A, Çatlı G, Abacı A, Böber E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab. 2015;19(2):267-271.
  21. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab. 2002;87(5):2090-2094.
  22. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab. 1999;84(10):3575-3578.
  23. Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22(1):49-54.
  24. Garn SM. Radiographic atlas of skeletal development of the hand and wrist. Am J Hum Genet. 1959;11(3):282.
  25. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291-303.
  26. Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv. 2012;9(3):343-354.
  27. Yoon JY, Kang MJ, Kim SY, Seo JY, Yang SW, Lee YA, et al. The relationship between initial body mass index and body mass index after one year of gonadotropin-releasing hormone agonist therapy in idiopathic true precocious puberty girls. Journal of Korean Society of Pediatric Endocrinology. 2011;16(3):165-1
  28. Aguiar AL, Couto-Silva AC, Vicente EJ, Freitas IC, Cruz T, Adan L. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab. 2006; 19(11):1327-1334.
  29. Lee SJ, Yang EM, Seo JY, Kim CJ. Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J. 2012; 48(1):27-31.
  30. Messaaoui A, Massa G, Tenoutasse S, Heinrichs C. Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (tripto-relin) in girls: breast development, skeletal
    maturation, height and weight evolution during and after treatment. Rev Med Brux. 2005;26(1):27-32. French.
  31. Klein KO, Larmore KA, de Lancey E, Brown JM, Considine RV, Hassink SG. Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. J Clin Endocrinol Metab. 1998;83(10):3469-3475.
  32. Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012;78(5-6):304-311.
  33. Park J, Kim JH. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22(1):27-35.
  34. Mansfield M, Rudlin C, Crigler Jr J, Karol K, Crawford J, Boepple P, et al. Changes in growth and serum growth hormone and plasma soipatomedin-c levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab. 1988;66(1):3-9.
  35. Davison KK, Susman EJ, Birch LL. Percent body fat at age 5 predicts earlier pubertal development among girls at age 9. Pediatrics. 2003;111(4 Pt 1):815-821.
  36. Yoon JW, Park HA, Lee J, Kim JH. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty. Korean J Pediatr. 2017; 60(12):395-402.

  

Iranian Journal of Neonatology
Volume 15, Issue 4
October 2024
Pages 10-16

Files

Share

How to cite

Statistics